Informa Unveils Scrip 100

Main Category: Pharma Industry / Biotech Industry
Article Date: 14 Dec 2008 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Scrip World Pharmaceutical News has published today the 2009 edition of the Scrip 100 - its flagship annual analysis of the pharmaceutical industry, providing data, research and expert opinion on the performance, prospects and current state of the biopharmaceuticals market.

Published by Informa Pharma and combining the expertise of many of Scrip's most experienced staffers with writers from other Informa products such as Pharmaprojects, Datamonitor and Citeline, the Scrip 100 provides an insightful encapsulation of the pharma industry as the sector's major players prepare for the challenges of the year ahead.

"In terms of both the outstanding quality of our data and the high calibre of our contributing analysts, the Scrip 100 serves as a valuable resource tool for the industry's key players," says John Davis, Managing Editor, Scrip World Pharmaceutical News.

"The 2009 edition of the Scrip 100 mirrors the structure of the recently relaunched Scrip news and analysis service - with chapters devoted to business issues, developments in R&D, policy and regulation, the clinical trials landscape and opportunities presented by the world's emerging markets," explains John.

Highlights of this year's edition of Scrip 100 include the biopharmaceutical sector's top 100 companies ranking; an interview with Fred Hassan on why he shunned early retirement in favour of transforming the fortunes of Schering-Plough; and the Scrip stock tracker - a look at the robustness of the pharma business model in light of extreme market volatility in 2008.

In addition, the Scrip 100 takes a close look at why oncology continues to capture the industry's imagination, outlines 2008 NME approvals in the US, Europe and Japan, and predicts what changes an Obama presidency and landslide mandate will mean for the branded pharma industry.

"We also take a look at trends in six key therapy areas which underline where pharma players are spending their R&D dollars and whether China will live up to its innovative potential to become a powerhouse of pharmaceutical R&D," says John.

"Our comprehensive and exciting line-up of news and features - together with a host of additional commentary and data - makes the 2009 edition of the Scrip 100 a must-read title for those hoping to influence and shape our industry during the year to come."

For a copy of the 2009 edition of Scrip 100, please log on to: http://www.scripnews.com/supplements from December 12th.

Scrip World Pharmaceutical